UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

______________

 

FORM 6-K/A

(Amendment No. 1)

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2013

 

Commission File Number: 001-34541

 

CHINA CORD BLOOD CORPORATION
(Translation of registrant’s name into English)

 

48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨   No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

 

 
 

 

EXPLANATORY NOTE

 

This Amendment No. 1 (the “Amendment”) to the Report of Foreign Issuer on Form 6-K (the “Original 6-K”), originally furnished by China Cord Blood Corporation (the “Company”) to the Securities and Exchange Commission on November 14, 2013, amends the Original 6-K to include an unaudited condensed consolidated statement of changes in equity, an unaudited condensed consolidated statements of cash flows, and notes to the unaudited condensed consolidated financial statements and the applicable interactive data file as Exhibit 101, which provides the unaudited condensed consolidated financial statements in XBRL (eXtensible business reporting language), and to provide for the incorporation by reference described below. No other changes have been made to the Original 6-K. This Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original 6-K.

 

This Amendment and each of the exhibits to this Amendment are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-168873, No. 333-183143 and No. 333-191121) of the Company.

 

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to confirm these statements to actual results, unless required by law.

 

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; compliance with restrictive debt covenants under the Company’s senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

 

 
 

 

Results of Operations and Financial Condition

 

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2013 of the Company.

 

 
 

 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets

(Amounts expressed in thousands, except share data)

 

      March 31,   September 30, 
   Note  2013   2013   2013 
      RMB   RMB   US$ 
ASSETS                  
                   
Current assets                  
Cash and cash equivalents      1,494,099    1,669,380    272,775 
Accounts receivable, less allowance for doubtful accounts (March 31, 2013: RMB14,112; September 30, 2013: RMB16,082 (US$2,628))      73,076    80,559    13,163 
Inventories      10,265    16,832    2,751 
Prepaid expenses and other receivables      11,602    14,844    2,425 
Debt issuance costs  5   3,678    3,606    589 
Deferred tax assets      5,454    5,985    978 
Total current assets      1,598,174    1,791,206    292,681 
                   
Property, plant and equipment, net  3   468,272    520,169    84,995 
Non-current prepayments      212,633    208,188    34,018 
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2013: RMB36,361; September 30, 2013: RMB38,346 (US$6,266))      249,370    236,064    38,572 
Inventories      39,730    42,933    7,015 
Intangible assets, net      125,170    122,860    20,075 
Available-for-sale equity securities      88,404    169,699    27,729 
Other investment      189,129    189,129    30,903 
Debt issuance costs  5   11,667    9,630    1,574 
Deferred tax assets      3,727    1,114    182 
Total assets      2,986,276    3,290,992    537,744 
                   
LIABILITIES                  
                   
Current liabilities                  
Bank loan  4   50,000    60,000    9,804 
Accounts payable      9,890    8,779    1,434 
Accrued expenses and other payables      84,006    64,942    10,611 
Deferred revenue      172,328    181,428    29,645 
Amounts due to related parties      11,241    720    118 
Income tax payable      4,983    2,206    360 
Deferred tax liabilities      -    1,300    212 
Total current liabilities      332,448    319,375    52,184 
                   
Convertible notes  5   751,781    754,807    123,334 
Non-current deferred revenue      530,258    665,226    108,697 
Other non-current liabilities      107,158    133,954    21,888 
Deferred tax liabilities      23,168    24,938    4,075 
Total liabilities      1,744,813    1,898,300    310,178 
                   
EQUITY                  
                   
Shareholders’ equity of China Cord Blood Corporation                  
Ordinary shares                  
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2013 and September 30, 2013, respectively      50    50    8 
Additional paid-in capital      798,221    798,221    130,429 
Treasury stock, at cost (March 31, 2013 and September 30, 2013: 136,899 shares, respectively)      (2,815)   (2,815)   (460)
Accumulated other comprehensive income      18,256    111,408    18,204 
Retained earnings      423,420    481,230    78,633 
Total equity attributable to China Cord Blood Corporation      1,237,132    1,388,094    226,814 
                   
Non-controlling interests      4,331    4,598    752 
                   
Total equity      1,241,463    1,392,692    227,566 
                   
Commitments and contingencies      -    -    - 
                   
Total liabilities and equity      2,986,276    3,290,992    537,744 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

1
 

 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income

(Amounts expressed in thousands, except share data)

 

      Three months ended September 30,   Six months ended September 30, 
   Note  2012   2013   2013   2012   2013   2013 
      RMB   RMB   US$   RMB   RMB   US$ 
                            
Revenues      128,462    141,635    23,143    243,792    270,356    44,176 
Direct costs      (27,057)   (27,360)   (4,471)   (51,446)   (51,852)   (8,473)
Gross profit      101,405    114,275    18,672    192,346    218,504    35,703 
                                  
Operating expenses                                 
Research and development      (1,860)   (2,310)   (377)   (4,123)   (4,833)   (790)
Sales and marketing      (23,517)   (27,633)   (4,515)   (42,737)   (56,057)   (9,160)
General and administrative      (28,984)   (28,042)   (4,582)   (54,044)   (55,444)   (9,059)
Total operating expenses      (54,361)   (57,985)   (9,474)   (100,904)   (116,334)   (19,009)
                                  
Operating income      47,044    56,290    9,198    91,442    102,170    16,694 
                                  
Other expense, net                                 
Interest income      3,859    4,312    705    7,188    8,494    1,388 
Interest expense      (14,089)   (16,461)   (2,690)   (24,265)   (31,219)   (5,101)
Exchange gain/(loss)      41    69    11    51    (55)   (9)
Dividend income      -    -    -    2,420    8,722    1,425 
Others      (1,002)   514    84    (766)   1,044    171 
Total other expense, net      (11,191)   (11,566)   (1,890)   (15,372)   (13,014)   (2,126)
                                  
Income before income tax      35,853    44,724    7,308    76,070    89,156    14,568 
                                  
Income tax expense  6   (8,466)   (19,706)   (3,220)   (14,801)   (31,079)   (5,078)
Net income      27,387    25,018    4,088    61,269    58,077    9,490 
                                  
Net income attributable to non-controlling interests      (2,692)   (114)   (19)   (5,481)   (267)   (44)
Net income attributable to China Cord                                 
Blood Corporation’s shareholders      24,695    24,904    4,069    55,788    57,810    9,446 
                                  
Net income per share:                                 
Attributable to ordinary shares  7                              
-    Basic      0.34    0.33    0.05    0.75    0.73    0.12 
-    Diluted      0.34    0.33    0.05    0.75    0.73    0.12 
                                  
Other comprehensive income                                 
-    Net effect of foreign currency translation, net of nil tax      (1,007)   2,789    456    (2,424)   9,594    1,568 
-    Net unrealized gain/(loss) in available-for-sale
     equity securities, net of nil tax
      2,624    59,220    9,676    (19,950)   83,558    13,653 
Comprehensive income      29,004    87,027    14,220    38,895    151,229    24,711 
                                  
Comprehensive income attributable to non-controlling interests      (2,672)   (114)   (19)   (5,459)   (267)   (44)
Comprehensive income attributable to China                                 
Cord Blood Corporation’s shareholders      26,332    86,913    14,201    33,436    150,962    24,667 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

2
 

 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statement of Changes in Equity

(Amounts expressed in thousands, except share data)

 

   China Cord Blood Corporation shareholders         
                       Accumulated             
   Share capital   Additional   Treasury stock   other       Non-     
   No. of       paid-in   No. of       comprehensive   Retained   controlling   Total 
   shares   Amount   capital   shares   Amount   income   earnings   interests   equity 
       RMB   RMB       RMB   RMB   RMB   RMB   RMB 
                                     
Balance as of April 1, 2013   73,140,147    50    798,221    (136,899)   (2,815)   18,256    423,420    4,331    1,241,463 
Net income   -    -    -    -    -    -    57,810    267    58,077 
Other comprehensive income   -    -    -    -    -    93,152    -    -    93,152 
Balance as of September 30, 2013   73,140,147    50    798,221    (136,899)   (2,815)   111,408    481,230    4,598    1,392,692 
                                              
Balance as of September 30, 2013 - US$       $8   $130,429        $(460)  $18,204   $78,633   $752   $227,566 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

3
 

 

China Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

(Amounts expressed in thousands)

 

   Six months ended September 30, 
   2012   2013   2013 
   RMB   RMB   US$ 
Cash flows from operating activities:               
Net cash provided by operating activities   279,406    229,623    37,521 
                
Cash flows from investing activities:               
Purchase of property, plant and equipment   (88,642)   (57,069)   (9,325)
Proceeds from disposal of property, plant and equipment   218    178    29 
Net cash used in investing activities   (88,424)   (56,891)   (9,296)
                
Cash flows from financing activities:               
Repayments of bank loan   (45,000)   (50,000)   (8,170)
Proceeds from bank loan   50,000    60,000    9,804 
Payments for repurchase of shares   (73,400)   (4,422)   (723)
Proceeds from issuance of convertible notes   412,292    -    - 
Payments for debt issuance costs   (3,532)   (3,242)   (530)
Net cash provided by financing activities   340,360    2,336    381 
                
Effect of foreign currency exchange rate change on cash and cash equivalents   (1,146)   213    35 
                
Net increase in cash and cash equivalents   530,196    175,281    28,641 
                
Cash and cash equivalents at beginning of period   794,311    1,494,099    244,134 
                
Cash and cash equivalents at end of period   1,324,507    1,669,380    272,775 
                
Supplemental disclosures of cash flow information:               
Cash paid for income taxes   17,404    30,888    5,047 
Cash paid for interest   1,703    51,670    8,443 
                
Non-cash financing activities:               
Payables for debt issuance costs   10,717    -    - 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

4
 

 

Notes to the unaudited condensed consolidated financial statements

(Amounts expressed in thousands, except share data)

 

1Principal activities and basis of presentation

 

(a)Principal activities

 

China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2013, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

 

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

 

(b)Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2013 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2013 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2013.

 

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2013, and the results of operations for the three and six months ended September 30, 2013 and 2012 and cash flows for the six months ended September 30, 2013 and 2012 have been made.

 

For the convenience of the readers, certain amounts as of and for the three and six months ended September 30, 2013 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.1200, being the spot exchange rate of U.S. dollars in effect on September 30, 2013 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2013 or at any other date.

 

5
 

  

2Summary of significant accounting policies

 

(a)Principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

 

(b)Use of estimates

 

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the recoverability of the carrying values of property, plant and equipment and intangible assets, the fair value of investment securities, the valuation allowances for receivables and deferred tax assets and the realizability of inventories.

 

3Property, plant and equipment, net

 

Property, plant and equipment, net consist of the following:

 

   March 31,   September 30, 
   2013   2013   2013 
   RMB   RMB   US$ 
             
Buildings   187,529    187,499    30,637 
Leasehold improvements   44,264    43,651    7,133 
Machineries   105,899    112,512    18,384 
Motor vehicles   11,087    13,221    2,160 
Furniture, fixtures and office equipment   27,588    32,166    5,256 
Construction-in-progress   205,657    259,323    42,373 
    582,024    648,372    105,943 
Less: Accumulated depreciation   (113,752)   (128,203)   (20,948)
Total property, plant and equipment, net   468,272    520,169    84,995 

 

In November 2012, the Group signed a refurbishment contract with a third party for the property of Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”). The contract amount was RMB110,000. As of March 31, 2013 and September 30, 2013, RMB43,468 and RMB63,954 (US$10,450) has been paid in accordance to the construction schedule and is included in construction-in-progress, respectively.

 

6
 

 

In April 2013, the Group signed refurbishment contracts with two third-parities for the property of Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”). Total contract amount was RMB69,300 (US$11,324), of which RMB12,474 (US$2,038) has been paid in accordance to the construction schedule. As of September 30, 2013, the buildings are under refurbishment and are included in construction-in-progress. The Group is in the process of obtaining the ownership certificate.

 

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2012 and 2013 was RMB7,160 and RMB7,560 (US$1,235), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2012 and 2013 was RMB13,926 and RMB14,998 (US$2,451), respectively.

 

As of March 31, 2013 and September 30, 2013, building with a carrying value of RMB121,603 and RMB118,048 (US$19,289) was collateralized for short-term bank loan of RMB50,000 and RMB60,000 (US$9,804) (see Note 4), respectively.

 

4Bank loan

 

On July 11, 2012, the Group borrowed RMB50,000 from Hangzhou Bank, a commercial bank in the PRC. The term of the loan is one year. The Group repaid the bank loan in full on July 10, 2013.

 

On August 12, 2013, the Group borrowed RMB60,000 (USD9,804) from Hangzhou Bank for one year with a due date on August 11, 2014. The loan bears interest rate at 7.2% per annum.

 

The bank loans are denominated in RMB and are collateralized by a building of the Group (see Note 3).

 

5Convertible notes

 

The carrying amount of the convertible notes to KKR China Healthcare Investment Limited (“KKRCHIL”) (the “KKR Notes”) and to Golden Meditech Holdings Limited (“GMHL”), which is a major shareholder of the Company (the “GM Notes”), (collectively the “Notes”), is summarized in the following table:

 

   March 31,   September 30, 
   2013   2013   2013 
   RMB   RMB   US$ 
             
Principal amount of the KKR Notes   409,764    401,887    65,667 
Principal amount of the GM Notes   315,226    309,192    50,522 
Cumulative interest payable   26,791    43,728    7,145 
Carrying amount   751,781    754,807    123,334 

 

The Company accrued interest on the Notes based on the guaranteed 12% IRR per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the unaudited condensed consolidated balance sheets. Debt issuance costs capitalized in connection with the issuance of the Notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years.

7
 

 

Interest relating to the Notes was recognized as follows:

 

   Three months ended September 30,   Six months ended September 30, 
   2012   2013   2013   2012   2013   2013 
   RMB   RMB   US$   RMB   RMB   US$ 
                         
KKR Notes interest incurred   12,512    12,190    1,992    21,337    24,320    3,974 
GM Notes interest incurred   -    9,496    1,552    -    18,827    3,076 
Amortization of debt issuance costs   767    912    149    1,225    1,819    297 
Interest cost capitalized   -    (6,600)   (1,078)   -    (14,789)   (2,417)
Total   13,279    15,998    2,615    22,562    30,177    4,930 

 

6Income tax

 

Effective from January 1, 2008, under the new Enterprise Income Tax (“EIT”) law, the PRC statutory income tax rate is 25%. The Company’s PRC subsidiaries are subject to income tax rate of 25% unless otherwise specified.

 

The new EIT law and its relevant regulations provide transitional tax rates for Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) which are 24% and 25% for calendar years 2011 and 2012 onwards, respectively. In February 2012, Beijing Jiachenhong received approval from the tax authority on the renewal of its “High and New Technology Enterprise” (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2013.

 

In June 2011, Guangzhou Nuoya received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2010 to December 31, 2012. Upon the expiration of the HNTE certificate, the tax rate applied to Guangzhou Nuoya would be 25% unless the HNTE status is renewed, which will enable it to preferential income tax rate of 15% from January 1, 2013 to December 31, 2015. For the period from January 1, 2013 to September 30, 2013, the Company has prepaid income tax at the rate of 25%. Management believes that Guangzhou Nuoya meets all the criteria for the renewal of HNTE status and accordingly, applied 15% tax rate to measure taxable temporary differences that are expected to reverse by the calendar year ending December 31, 2015.

 

The Company’s effective income tax rates for the three months ended September 30, 2012 and 2013 were 23.6% and 44.1%, and were 19.5% and 34.9% for the six months ended September 30, 2012 and 2013, respectively. The effective income tax rates for the three and six months ended September 30, 2013 differ from the PRC statutory income tax rate of 25% primarily due to the effect of Beijing Jiachenhong and Guangzhou Nuoya’s preferential tax treatments, which is offset by the effect of non-PRC entities not being subject to income tax.

 

As of and for the six months ended September 30, 2013, the Company did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

 

8
 

 

7Net income per share

 

The following table sets forth the computation of basic net income per share and diluted net income per share for the three and six months ended September 30, 2012 and 2013 respectively:

 

      Three months ended September 30, 
   Note  2012   2013   2013 
      RMB   RMB   US$ 
Numerator:                  
Net income attributable to the Company’s shareholders      24,695    24,904    4,069 
Earnings allocated to participating convertible notes  (i)   (491)   (722)   (118)
                   
Net income for basic and diluted net income per share      24,204    24,182    3,951 
                   
Denominator:                  
Weighted average ordinary shares outstanding for basic and diluted net income per share      69,860,425    73,003,248    73,003,248 
                   
Net income per share attributable to ordinary shares:                  
-   Basic      0.34    0.33    0.05 
-   Diluted  (ii)   0.34    0.33    0.05 

 

      Six months ended September 30, 
   Note  2012   2013   2013 
      RMB   RMB   US$ 
Numerator:                  
Net income attributable to the Company’s shareholders      55,788    57,810    9,446 
Earnings allocated to participating convertible notes  (i)   (1,813)   (4,417)   (722)
                   
Net income for basic and diluted net income per share      53,975    53,393    8,724 
                   
Denominator:                  
Weighted average ordinary shares outstanding for basic and diluted net income per share      71,502,502    73,003,248    73,003,248 
                   
Net income per share attributable to ordinary shares:                  
-   Basic      0.75    0.73    0.12 
-   Diluted  (ii)   0.75    0.73    0.12 

 

Notes:

 

(i)The KKR Notes and GM Notes provide KKRCHIL and GMHL with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company is reduced by such allocated earnings to participating convertible notes for each reporting period in both basic and diluted net income per share computation.

 

9
 

 

(ii)During the three and six months ended September 30, 2012 and 2013, the Company had potentially dilutive ordinary shares of 22,903,454 and 40,521,495 representing shares issuable upon conversion of the Notes (see Note 5), respectively. Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

 

8Subsequent events

 

Subsequent to the period end and up to December 12, 2013, the Group has further paid RMB82,000 (US$13,399) for the refurbishment project of Guangzhou Nuoya and Zhejiang Lukou.

 

10
 

 

Other Events

 

On November 14, 2013, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and six months ended September 30, 2013. A copy of the press release is attached as Exhibit 99.1.

 

Exhibits

 

Exhibit No.   Description
99.1*   Press Release, dated November 14, 2013
101.INS XBRL   Instance Document
101.SCH XBRL   Taxonomy Extension Schema Document
101.CAL XBRL   Taxonomy Extension Calculation Linkbase Document
101.LAB XBRL   Taxonomy Extension Label Linkbase Document
101.PRE XBRL   Taxonomy Extension Presentation Linkbase Document

 

* Previously filed.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHINA CORD BLOOD CORPORATION  
  By: /s/ Albert Chen  
  Name: Albert Chen  
  Title: Chief Financial Officer  

 

Dated: December 12, 2013